Company news
Lexaria Bioscience Corp. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
April 23, 2025
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
April 3, 2025
Lexaria Updates Its Ongoing Human Study GLP-1-H24-4
April 2, 2025
Lexaria's Human GLP-1 Study #5 Begins Dosing
April 2, 2025
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
March 18, 2025
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
February 27, 2025
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
February 24, 2025
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
February 20, 2025
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
February 10, 2025
Lexaria Biodistribution Study for DehydraTECH GLP-1 is Underway
February 5, 2025
Lexaria Releases Annual Letter From the CEO
January 29, 2025
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
January 14, 2025
Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval
January 14, 2025
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half With Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound
January 13, 2025
Lexaria's Registered GLP-1 Study #4 Begins Dosing
December 18, 2024
Lexaria Forms New Scientific Advisory Board
December 17, 2024
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
November 24, 2024
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
November 13, 2024
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
November 12, 2024
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
October 23, 2024
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
October 15, 2024
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
October 14, 2024
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
October 8, 2024
Lexaria Appoints Michael Shankman as Chief Financial Officer
September 30, 2024
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
September 26, 2024
Lexaria Welcomes Industry Veteran as New CEO
September 4, 2024
Lexaria Releases Strategic Letter from the Outgoing CEO
September 4, 2024
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
September 2, 2024
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
August 28, 2024
First Results from Lexaria's Second GLP-1 Human Pilot Study
August 26, 2024
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
August 21, 2024
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
August 20, 2024
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
July 16, 2024
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
July 8, 2024
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
July 7, 2024
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
June 17, 2024
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
May 22, 2024
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
May 20, 2024
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
May 7, 2024
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
April 15, 2024
Lexaria Awarded New Patents
April 1, 2024
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
March 13, 2024
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
March 6, 2024
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
March 4, 2024
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
February 29, 2024
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 15, 2024
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 14, 2024
Lexaria's Submits Investigational New Drug Application
January 29, 2024
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
January 15, 2024
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
January 8, 2024
Decks
- Investor Presentation (December 2020)
Investor deck · 30 slides · Dec 31, 2020
- Investor Presentation (July 2019)
Investor deck · 27 slides · July 2019
- Investor Presentation (November 2017)
Investor deck · 16 slides · Nov 2, 2017